NASDAQHealth CareMedical Care FacilitiesSnapshot 2026-07-23
Reading PIII? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a speculative growth opportunity due to its current loss-making status and volatile management. The thesis remains intact despite recent challenges, as the company is working towards significant revenue targets.
The market seems to factor in a high level of risk given the company's loss-making status and recent legal/regulatory issues. However, the recent positive earnings surprise may suggest that some optimism is still present regarding future performance.
Management is focused on increasing revenue, with progress noted in recent quarters. However, the mixed status of adjusted EBITDA and a high probability of missing earnings expectations indicate potential volatility in fundamentals.
The future performance of PIII depends on its ability to meet revenue targets and manage compliance with Nasdaq listing rules. Additionally, the performance of sector bellwethers like HCA, THC, and DVA will be crucial in determining the overall momentum for PIII.
Over the next 1 to 3 years, PIII's trajectory will largely depend on management execution and sector performance. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Meeting this target shows progress towards the $1.5B-$1.7B revenue goal for 2026.
Confirms:Q2 revenue reported at or above $400M.
Disproves:Q2 revenue reported below $400M.
Why it matters: Updates will show if P3 can keep its Nasdaq listing due to compliance issues.
Confirms:A good update shows they follow Nasdaq listing rules.
Disproves:Further notice of delisting or failure to comply with Nasdaq rules.
Why it matters: Successful M&A could enhance growth prospects and support revenue targets.
Confirms:There is an announcement about a completed M&A deal or major progress.
Disproves:No updates or progress on the announced M&A activity.
Why it matters: Achieving this target is key to the $40M EBITDA goal for 2026.
Confirms:Adjusted EBITDA reported at or above $10M for Q2.
Disproves:Adjusted EBITDA was below $10M for Q2.
Why it matters: Compliance is key to avoid delisting and keep investor trust.
Confirms:P3 Health Partners confirms it meets Nasdaq listing requirements.
Disproves:P3 Health Partners gets another delisting notice from Nasdaq.
Why it matters: Meeting revenue guidance is key to proving management's growth plan.
Confirms:Total revenue reaches at least $1.5 billion for the year.
Disproves:Total revenue falls below $1.5 billion for the year.
